来那度胺联合R-ESHAP治疗复发或难治性弥漫性大B细胞淋巴瘤:GELTAMO的2期研究
该2期研究评估来那度胺联合R-ESHAP(LR-ESHAP)方案在复发或难治性弥漫性大B细胞淋巴瘤(DLBCL)患者中的安全性和疗效,共纳入46例患者。3周期后总缓解率(ORR)为67%,完全缓解率35%;原发性难治患者ORR显著低于非难治患者(54% vs 85%,p=0.031)。中位随访41个月,估计3年无进展生存(PFS)率和总生存(OS)率分别为42%和48%。
要点
- LR-ESHAP方案在复发或难治性DLBCL中ORR为67%,完全缓解率35%。
- 原发性难治患者ORR显著低于非难治患者(54% vs 85%,p=0.031)。
- 中位随访41个月,估计3年PFS率42%、OS率48%;28例(61%)接受自体干细胞移植。
核心结论
- 作者认为LR-ESHAP是一种可行的挽救方案,在复发或难治性DLBCL患者中显示出有希望的疗效结果。
研究设计与样本
- 该研究为2期临床试验,纳入46例复发或难治性弥漫性大B细胞淋巴瘤患者。
- 受试者接受3个周期来那度胺10 mg/天(每21天周期的第1-14天)联合标准剂量R-ESHAP方案。
- 缓解患者接受自体干细胞移植(ASCT),并进行集中性细胞起源(COO)分类。
- 主要终点为3个周期后的总缓解率(ORR)。
主要发现
- LR-ESHAP治疗后ORR为67%,其中35%的患者达到完全缓解。
- 原发性难治患者(n=26)的ORR显著低于非难治患者(54% vs 85%,p=0.031)。
- 未观察到不同COO分类之间缓解率的差异。
- 28例患者(61%)接受了ASCT。
- 中位随访41个月,估计3年PFS率为42%,3年OS率为48%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse large B-cell lymphoma (DLBCL) patients with relapsed or refractory (RR) disease have poor outcomes with current salvage regimens. We conducted a phase 2 trial to analyse the safety and efficacy of adding lenalidomide to R-ESHAP (LR-ESHAP) in patients with RR DLBCL. Subjects received 3 cycles of lenalidomide 10 mg/day on days 1-14 of every 21-day cycle, in combination with R-ESHAP at standard doses. Responding patients underwent autologous stem-cell transplantation (ASCT). The primary endpoint was the overall response rate (ORR) after 3 cycles. Centralized cell-of-origin (COO) classification was performed. Forty-six patients were included. The ORR after LR-ESHAP was 67% (35% of patients achieved complete remission). Patients with primary refractory disease (n = 26) had significantly worse ORR than patients with non-refractory disease (54% vs. 85%, p = 0.031). No differences in response rates according to the COO were observed. Twenty-eight patients (61%) underwent ASCT. At a median follow-up of 41 months, the estimated 3-year PFS and OS were 42% and 48%, respectively. The most common grade ≥3 adverse events were thrombocytopenia (70% of patients), neutropenia (67%) and anaemia (35%). There were no treatment-related deaths during LR-ESHAP cycles. In conclusion, LR-ESHAP is a feasible salvage regimen with promising efficacy results for patients with RR DLBCL.
引用
- Martín García-Sancho A, Baile M, Rodríguez G, et al. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO. Br J Haematol. 2023. PMID: 37485564. doi:10.1111/bjh.18989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。